Disease-modifying anti-rheumatic drugs (DMARDs) for Sjogren’s syndrome

Roberta Gualtierotti; Matteo Rota; María A. López-Olivo; F. Spadari; Carlo La Vecchia; Massimo Cugno

doi:10.1002/14651858.cd014529

Abstract

1 min read

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the benefits and harms of DMARDs in the treatment of Sjögren’s syndrome.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2021

Continuous infusion versus bolus injection of loop diuretics for congestive heart failure

Juqian Zhang, Can Zhou, Mahnoor Ihsan, Andreas A Tsangarides, Sarah Ahmed, Ranga Fernando, Tin Sanda Lwin, Shazmeen Surtee, Ebony Farnell, Muhammad Chaudhary, Professor Gregory Lip, Ruaraidh Hill, Rajiv Sankaranarayanan

Article2013

Psychosocial interventions in the emergency centre setting for preventing reinjury due to interpersonal violence

Claire van der Westhuizen, Katherine Sorsdahl, Gail E. Wyatt, John K. Williams, Nandi Siegfried, Dan Joseph Stein

Article2019

Transcranial magnetic stimulation for post-traumatic stress disorder

Jonathan Ipser, Nirvana Pillay, Dan Joseph Stein, Jack van Honk

Article2014

Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse

Henk Temmingh, Taryn Amos, Nandi Siegfried, Dan Joseph Stein

Article2014

Antidepressants for depression in adults with HIV infection

Ingrid Eshun‐Wilson, Dickens Akena, Nandi Siegfried, Ekwaro A. Obuku, Dan Joseph Stein, John A. Joska